Cargando…

Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects

Concomitant administration of lobeglitazone, empagliflozin, and metformin is expected to enhance blood glucose-lowering effects and improve medication compliance in patients with diabetes mellitus. In this study, we investigated the pharmacokinetic (PK) interactions and safety of lobeglitazone and c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Heeyoung, Kim, Choon Ok, Park, Hyeonsoo, Park, Min Soo, Kim, Dasohm, Hong, Taegon, Shin, Yesong, Jin, Byung Hak
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society for Clinical Pharmacology and Therapeutics 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079507/ https://www.ncbi.nlm.nih.gov/pubmed/37034122 http://dx.doi.org/10.12793/tcp.2023.31.e4

Ejemplares similares

Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers
por: Kim, Dasohm, et al.
Publicado: (2023)

The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male
por: Kim, Dasohm, et al.
Publicado: (2019)

Comparison of the pharmacokinetics and pharmacodynamics of YH4808 in healthy subjects for defining an appropriate dosing regimen
por: Yoon, Sukyong, et al.
Publicado: (2021)

Pharmacokinetic drug interaction between atorvastatin and ezetimibe in healthy Korean volunteers
por: Park, Jungsin, et al.
Publicado: (2017)

Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects
por: Lee, Woo Yul, et al.
Publicado: (2020)

Comparison of pharmacokinetics and safety of fixed-dose combination of SKI306X and aceclofenac versus separate tablets in healthy subjects
por: Meng, Xue, et al.
Publicado: (2017)

No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects
por: Kim, Yu Kyong, et al.
Publicado: (2021)

Effect of Rifampicin on the Pharmacokinetics of Evogliptin in Healthy Volunteers
por: Shin, Yesong, et al.
Publicado: (2022)

Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers
por: Choi, Chungam, et al.
Publicado: (2018)

Pharmacodynamic evaluation of YH4808 for Helicobacter pylori eradication in healthy subjects
por: Park, Hyeonsoo, et al.
Publicado: (2020)

Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects
por: Jiang, Xu, et al.
Publicado: (2023)

Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects
por: Kim, Choon Ok, et al.
Publicado: (2016)

Lobeglitazone Attenuates Airway Inflammation and Mucus Hypersecretion in a Murine Model of Ovalbumin-Induced Asthma
por: Shin, Na-Rae, et al.
Publicado: (2018)

Effects of Lobeglitazone, a Novel Thiazolidinedione, on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus over 52 Weeks
por: Lim, Soo, et al.
Publicado: (2017)

Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin
por: Jung, Jin Ah, et al.
Publicado: (2015)

Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus
por: Bae, Jaehyun, et al.
Publicado: (2021)

Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ
por: Jang, Jun Young, et al.
Publicado: (2018)

Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
por: Kim, Kyung-Soo, et al.
Publicado: (2020)

Efficacy and Safety of Lobeglitazone Monotherapy in Patients with Type 2 Diabetes Mellitus over 24-Weeks: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial
por: Kim, Sin Gon, et al.
Publicado: (2014)

Effects of Lobeglitazone, a New Thiazolidinedione, on Osteoblastogenesis and Bone Mineral Density in Mice
por: Kim, Kyoung Min, et al.
Publicado: (2017)

The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects
por: Zong, Jian, et al.
Publicado: (2014)

The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects
por: Song, Ivy H., et al.
Publicado: (2016)

Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions?
por: Kim, Choon Ok, et al.
Publicado: (2017)

Population pharmacokinetics of intravenous sufentanil in critically ill patients supported with extracorporeal membrane oxygenation therapy
por: Hahn, Jongsung, et al.
Publicado: (2019)

Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice
por: Seo, Da Hea, et al.
Publicado: (2022)

Effects of lobeglitazone on insulin resistance and hepatic steatosis in high-fat diet-fed mice
por: Choi, Bong-Hoi, et al.
Publicado: (2018)

Treatment with Lobeglitazone Attenuates Hepatic Steatosis in Diet-Induced Obese Mice
por: Choung, Sorim, et al.
Publicado: (2018)

Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naïve patients with type 2 diabetes: initial triple study
por: Lim, Soo, et al.
Publicado: (2020)

A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus
por: Kim, Bo-Yeon, et al.
Publicado: (2022)

Pharmacokinetics and Bioequivalence of Two Empagliflozin, with Evaluation in Healthy Jordanian Subjects under Fasting and Fed Conditions
por: Hailat, Mohammad, et al.
Publicado: (2022)

Lobeglitazone inhibits LPS-induced NLRP3 inflammasome activation and inflammation in the liver
por: Seo, Hye-Young, et al.
Publicado: (2023)

Pharmacokinetic-pharmacodynamic analysis to evaluate the effect of moxifloxacin on QT interval prolongation in healthy Korean male subjects
por: Hong, Taegon, et al.
Publicado: (2015)

Empagliflozin and Renal Sodium-Hydrogen Exchange in Healthy Subjects
por: Biancalana, Edoardo, et al.
Publicado: (2023)

Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects
por: Hausner, Helene, et al.
Publicado: (2017)

Effects of Simvastatin on Pharmacokinetics and Anticoagulant Effects of Dabigatran in Healthy Subjects
por: Chung, Hyewon, et al.
Publicado: (2023)

Population pharmacokinetics of remifentanil in critically ill patients receiving extracorporeal membrane oxygenation
por: Yang, Seungwon, et al.
Publicado: (2017)

Comparison of the Pharmacokinetic–Pharmacodynamic Relationships of Two Darbepoetin Alfa Formulations in Healthy Male Volunteers
por: Kim, Seokuee, et al.
Publicado: (2018)

A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects
por: Park, Sang-In, et al.
Publicado: (2015)

Effect of Cilostazol on the Pharmacokinetics of Simvastatin in Healthy Subjects
por: Kim, Jung-Ryul, et al.
Publicado: (2019)

Bioequivalence of the pharmacokinetics between tofacitinib aspartate and tofacitinib citrate in healthy subjects
por: Shin, Wonsuk, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2tqqlf4ej9o8nr8dgkk4a18qgt